ImmuCell Corporation (ICCC:NASDAQ) closed at $9.80 on November 6, 2026, down 1.51% on the day. The stock trades 19.0% below its 52-week high of $12.10 and 116.8% above its 52-week low of $4.52. Over the past year, it gained 60.7%. ImmuCell Corporation is part of the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances).
In 252 trading sessions since November 6, 2025, ICCC closed higher on 124 days (49%). Its best day was April 9, 2026 (+12.70%) and its worst was November 14, 2025 (-10.74%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity in the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product that provides bovine antibodies for newborn calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. T...
Find more stocks like ICCC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.